ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectively Rare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited results Provides full year 2026 financial guidance, which includes: Total net revenues of $1,055 million to $1,115 million Cortrophin Gel net revenues of $540 million to $575 million Adjusted non-GAAP EBITDA of $275 million to $290 million Rare Disease business to represent approximately 60% of total net revenues Announces ~90-person expansion of Rare Disease organization to capture unique opportunity for Cortrophin Gel in acute gouty arthritis flares; expected to deploy in mid-2026 PRINCETON, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced preliminary select financial results for full year 2025, provided full year 2026 financial guidance, and outlined its strategic priorities for continued growth.

GlobeNewsWire • 21 hours ago

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.

GlobeNewsWire • Jan 6, 2026

ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?

ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.

Zacks Investment Research • Jan 6, 2026

Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?

ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.

Zacks Investment Research • Jan 2, 2026

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 31, 2025

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away

Oregon-based Stonepine Capital Management sold all 38,597 shares of its ANI Pharmaceuticals shares in the third quarter. The shares were worth about $2.52 million.

The Motley Fool • Dec 28, 2025

Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research • Dec 22, 2025

3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026

EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.

Zacks Investment Research • Dec 22, 2025

Zacks Industry Outlook Arcutis, Amicus and ANI

Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.

Zacks Investment Research • Dec 18, 2025

5 Biotech Stocks to Watch for Potential Upside

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.

Zacks Investment Research • Dec 17, 2025